AUC of various models to predict imeglimin efficacy for liver function evaluated by ROC curves. حسب Naruyoshi Gyoutoku (22537831)

الموضوعات:

The ROC curves and AUC values of the diagnostic model. حسب Zhe Wu (582498)

ROC curve and AUC value of all models. حسب Tiago de Oliveira Barreto (20485207)

"…As for Specificity (82.94%) and ROC-AUC (82.13%), the Multilayer Perceptron with SGD optimizer obtained the highest scores. …"

Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

Inhibition of NEAT1 decreased the miR-204-5p expression and increased Six1 expression. حسب Lei Li (29537)

"…<p>(A) NEAT1 expression following siRNA transfection in BEAS-2B cells; (B-D) The expression of NEAT1, miR-204-5p, and Six1 after decreasing NEAT1 expression. * p <0.05, *** p < 0.001, and **** p <0.0001.…"

Area under the curve (AUC) for external validation performance. حسب Junichi Kushioka (12236447)

A path model of six-factor self-compassion. حسب Eriko Takahashi (22608061)

Sleep deprivation increased inflammatory cytokines and decreased corticosterone in the blood. حسب Weiran Shan (16969688)

Column charts of WiAUC in therapy and control group at baseline and follow-up. حسب Felix L. Herr (21544362)

AUC ROC curve. حسب Dieuwke Luijten (15282736)

Mode shapes of the first six modes. حسب Xueting Ma (390540)

Statistical analysis of the AUC measurement. حسب Esra Ayan (21156015)

"…<p>Analysis indicated that INSv application significantly changed spontaneous calcium activity (IAsp <i>p</i>-value: 0.1290, INSv <i>p</i>-value: 0.0002). The mean AUC decreased in both samples.…"

Area under the ROC Curve (AUC) analysis to predict AIS conversion at 6-months and 1-year following acute cervical tSCI. حسب Harshit Arora (22008280)

Area under the ROC curve (AUC) analysis to predict neurological severity at 6-months and 1-year following acute cervical tSCI. حسب Harshit Arora (22008280)

Trends in average work volume (in hrs.) in six focal countries, 1992–2022. حسب Lena Hipp (11720192)

a-d. Difference in (a) probing depth; (b) clinical attachment level; (c) bleeding on probing, and (d) plaque index values between baseline and six months after treatment using syst... حسب Iva Milinkovic (22331710)

Difference in (a) IL-17, and (b) TNF-α relative gene expression levels between baseline and six months after treatment using systemic and local antibiotic treatment. حسب Iva Milinkovic (22331710)

Daily number of adverse outcomes (bars) and area under the precision-recall curve (AUC-PRC) per day of the fullPIERS model. حسب Guiyou Yang (10259597)

Daily number of adverse outcomes (bars) and area under the precision-recall curve (AUC-PRC) per day of the PIERS-ML model. حسب Guiyou Yang (10259597)

A summary of the included study characteristics. حسب Zahra Tajik (20752452)

"…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"